<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir (FPV) may be one of the possible treatment options for COVID-19 [
 <xref rid="B109-jcm-09-01917" ref-type="bibr">109</xref>]. It has been shown that FPV is able to inhibit virus reproduction in vitro. Preliminary studies comparing favipiravir treatment with lopinavir/ritonavir reported shorter viremic clearance (4 vs. 11 days) and improved radiological picture in the FPV group [
 <xref rid="B110-jcm-09-01917" ref-type="bibr">110</xref>]. Irie et al. investigated the pharmacokinetics of FPV in the context of COVID-19 treatment showed that the drug concentration was lower in critically ill patients compared to healthy individuals, indicating the need for using higher doses [
 <xref rid="B111-jcm-09-01917" ref-type="bibr">111</xref>]. Lack of more accurate data requires in-depth research in this area.
</p>
